a randomised double-blind placebo-controlled clinical trial was undertaken to assess survival after a single 30 unit intravenous dose of anisoylated plasminogen streptokinase activator complex ( apsac ) within 6 h of onset of acute myocardial infarction .
C0078956
anisoylated
C0027051
myocardial infarction